듀셴형 근이영양증(DMD) 역학 분석 및 예측(2026년)

The Global Duchenne Muscular Dystrophy prevelance is projected to increase at a CAGR of 2.5% for the forecast period, growing from 0.43 million patients in 2026 to 0.54 million patients by 2035.

Duchenne Muscular Dystrophy (DMD) is a rare, severe, X-linked genetic neuromuscular disorder caused by mutations in the dystrophin gene. The disease primarily affects males and is characterized by progressive muscle degeneration, loss of ambulation, respiratory decline, cardiac complications, and reduced life expectancy. As one of the most common forms of muscular dystrophy in children, DMD imposes a substantial burden on patients, caregivers, healthcare systems, and society. Although the disease remains relatively rare, increasing diagnostic capabilities and enhanced disease awareness are improving identification rates and expanding the understanding of global patient populations.

Epidemiology analysis plays a crucial role in evaluating disease prevalence, incidence, mutation distribution, diagnosed patient populations, demographic characteristics, disease progression patterns, survival trends, and treatment eligibility. Pharmaceutical companies, biotechnology firms, healthcare providers, policymakers, and research organizations increasingly depend on epidemiological intelligence to support clinical trial planning, market forecasting, healthcare resource allocation, and rare disease strategy development. As innovative therapies continue to emerge, accurate epidemiological assessments are becoming even more important for understanding patient needs and commercial opportunities.

Market Drivers

Increasing Adoption of Genetic Testing

One of the primary drivers of market growth is the expanding use of genetic testing technologies. Advances in molecular diagnostics, next-generation sequencing, and mutation analysis have significantly improved the accuracy and speed of DMD diagnosis.

Earlier and more reliable diagnosis enables healthcare providers to identify affected individuals sooner, improving patient management and strengthening epidemiological databases. The growing availability of genetic testing services is contributing to more comprehensive disease surveillance and population analysis.

Growing Awareness of Rare Genetic Disorders

Awareness campaigns led by healthcare organizations, patient advocacy groups, and research institutions are improving recognition of DMD among healthcare professionals and the general public.

Enhanced awareness promotes earlier diagnosis, increased participation in patient registries, and improved reporting of disease cases. These developments support more accurate estimates of disease prevalence and incidence across different regions.

Expansion of Patient Registries and Disease Databases

National and international patient registries are becoming increasingly important sources of epidemiological information. These databases collect valuable data regarding patient demographics, genetic mutations, disease progression, treatment patterns, and long-term outcomes.

The expansion of patient registries is improving understanding of disease burden and supporting more sophisticated epidemiological forecasting models.

Growth in Therapeutic Development Activities

The increasing number of DMD therapies under development is creating substantial demand for patient population intelligence. Drug developers require detailed epidemiological data to support clinical trial recruitment, regulatory submissions, market access planning, and commercial forecasting.

As personalized and mutation-specific therapies become more common, the importance of precise patient segmentation continues to grow.

Market Restraints

Underdiagnosis in Developing Regions

Many patients in low- and middle-income countries remain undiagnosed due to limited access to specialized healthcare services, genetic testing facilities, and neuromuscular disease expertise.

Underdiagnosis can result in incomplete epidemiological assessments and may affect the accuracy of global prevalence estimates.

Variability in Diagnostic Practices

Differences in diagnostic criteria, healthcare infrastructure, and disease reporting systems across countries can create inconsistencies in epidemiological data collection.

These variations may complicate comparisons between regions and introduce uncertainty into patient population forecasts.

Limited Long-Term Data Availability

Although patient registries continue to expand, long-term epidemiological data remain limited in some regions. Incomplete datasets may affect the ability to accurately assess disease progression patterns, survival outcomes, and future patient population trends.

Addressing these data gaps remains an important priority for researchers and healthcare organizations.

Technology and Segment Insights

The global Duchenne Muscular Dystrophy epidemiology analysis market can be segmented by patient category, disease stage, mutation type, data source, application, end user, and geography.

By patient category, the market includes prevalent cases, incident cases, diagnosed patients, undiagnosed patients, treated patients, untreated patients, and genetically confirmed patients. Diagnosed and genetically confirmed patients represent significant segments due to the growing use of molecular diagnostic technologies and increasing treatment eligibility assessments.

By disease stage, the market includes early-stage disease, ambulatory patients, non-ambulatory patients, advanced disease, and patients with significant respiratory or cardiac involvement. Early-stage and ambulatory patient populations are receiving increased attention due to the growing availability of therapies designed to intervene before severe disease progression occurs.

By mutation type, the market includes exon deletions, exon duplications, point mutations, nonsense mutations, splice-site mutations, and other genetic abnormalities. Mutation-specific epidemiological analysis is becoming increasingly important as precision medicine approaches target specific genetic subgroups.

By data source, the market includes patient registries, hospital databases, electronic health records, genetic testing laboratories, academic research studies, insurance databases, and government health registries. Patient registries and genetic databases play a central role in disease surveillance and patient population tracking.

By application, the market encompasses prevalence analysis, incidence analysis, disease burden assessment, treatment eligibility evaluation, clinical trial feasibility studies, healthcare planning, and commercial opportunity assessment. Treatment eligibility analysis is becoming increasingly important as advanced therapies target specific patient populations.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms. Pharmaceutical and biotechnology companies account for a major share of demand due to increasing investment in DMD therapeutic development.

Technological advancements are transforming epidemiological analysis through artificial intelligence, predictive analytics, genomics platforms, real-world evidence systems, electronic health records, and integrated patient databases. These technologies improve patient identification, disease modeling, mutation analysis, and long-term forecasting capabilities.

The growing integration of genetic information with epidemiological datasets is enabling more precise patient stratification and supporting the development of targeted treatment approaches. Advanced analytics platforms are also improving the accuracy of prevalence forecasting and healthcare resource planning.

Geographically, North America represents the leading market due to advanced genetic testing infrastructure, strong rare disease research activity, established patient registries, and extensive therapeutic development programs. Europe maintains a significant position supported by collaborative neuromuscular disease networks, comprehensive healthcare systems, and rare disease initiatives. Asia-Pacific is expected to experience substantial growth due to improving healthcare infrastructure, expanding genetic testing access, increasing disease awareness, and growing investments in rare disease research. Latin America and the Middle East & Africa are gradually strengthening diagnostic capabilities and epidemiological surveillance programs.

Competitive and Strategic Outlook

The competitive landscape is characterized by increasing collaboration among pharmaceutical companies, biotechnology firms, patient advocacy organizations, academic institutions, healthcare providers, and epidemiological research organizations.

Stakeholders are investing in patient registries, genetic databases, real-world evidence platforms, and advanced analytics capabilities to improve understanding of disease prevalence and patient demographics. Strategic partnerships are helping organizations expand access to epidemiological data, improve patient identification, and support therapeutic development initiatives.

The increasing focus on personalized medicine and mutation-specific therapies is creating demand for more detailed epidemiological segmentation. Companies are utilizing advanced population analysis to identify treatment-eligible patients, optimize clinical trial recruitment, and support future commercialization strategies.

As therapeutic innovation continues to accelerate, epidemiological intelligence will remain a critical component of strategic decision-making across the DMD healthcare ecosystem.

Conclusion

The global Duchenne Muscular Dystrophy epidemiology analysis market is poised for sustained growth through 2031, supported by increasing adoption of genetic testing, expanding patient registries, growing awareness of rare genetic disorders, and rising investment in therapeutic development. Comprehensive epidemiological analysis remains essential for understanding disease burden, supporting healthcare planning, guiding clinical research, and enabling successful commercialization of emerging therapies. Although challenges related to underdiagnosis, regional data variability, and limited long-term datasets persist, ongoing advancements in genomics, healthcare informatics, and patient data integration are expected to significantly improve the accuracy and value of DMD epidemiological intelligence in the coming years.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
• 1.2 Key Findings
• 1.3 Duchenne Muscular Dystrophy (DMD) Epidemiology Snapshot
• 1.4 Historical and Forecast Disease Burden (2025-2045)
• 1.5 Key Epidemiological Trends and Insights
• 1.6 High-Growth Opportunities and Unmet Needs
• 1.7 Key Strategic Conclusions

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Duchenne Muscular Dystrophy
  • 2.1.1 Disease Definition
  • 2.1.2 Disease Pathophysiology
  • 2.1.3 Genetic Basis and Dystrophin Gene Mutations
  • 2.1.4 Disease Progression and Natural History
  • 2.1.5 Clinical Manifestations
• 2.2 Disease Classification and Mutation Subtypes
  • 2.2.1 Exon 45 Amenable Population
  • 2.2.2 Exon 51 Amenable Population
  • 2.2.3 Exon 53 Amenable Population
  • 2.2.4 Nonsense Mutation DMD
  • 2.2.5 Other Mutation Types
  • 2.2.6 Ambulatory vs Non-Ambulatory Population
• 2.3 Risk Factors and Disease Burden
  • 2.3.1 Genetic Risk Factors
  • 2.3.2 Family History and Carrier Status
  • 2.3.3 Mortality and Survival Trends
  • 2.3.4 Quality-of-Life Burden
  • 2.3.5 Economic Burden of Disease
• 2.4 Epidemiology Methodology
  • 2.4.1 Data Sources and Assumptions
  • 2.4.2 Epidemiology Modeling Framework
  • 2.4.3 Forecasting Methodology (2025-2045)
• 2.5 Global Epidemiology Analysis
  • 2.5.1 Incident Cases
  • 2.5.2 Prevalent Cases
  • 2.5.3 Diagnosed Prevalent Cases
  • 2.5.4 Treated Patient Population
  • 2.5.5 Mutation-Specific Patient Population
  • 2.5.6 Age-Specific Distribution
  • 2.5.7 Severity-Based Distribution
  • 2.5.8 Ambulatory and Non-Ambulatory Population Analysis
• 2.6 Epidemiology Forecast (2025-2045)
  • 2.6.1 Global Incidence Forecast
  • 2.6.2 Global Prevalence Forecast
  • 2.6.3 Diagnosed Population Forecast
  • 2.6.4 Treatment-Eligible Population Forecast
  • 2.6.5 Mutation-Specific Forecast

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Drivers
  • 3.2.1 Increasing Genetic Testing and Early Diagnosis
  • 3.2.2 Growing Adoption of Mutation-Specific Therapies
  • 3.2.3 Advancements in Gene Therapy
  • 3.2.4 Expansion of Rare Disease Funding Programs
  • 3.2.5 Improved Patient Survival Rates
• 3.3 Restraints
  • 3.3.1 High Cost of Treatment
  • 3.3.2 Limited Eligible Patient Populations
  • 3.3.3 Regulatory and Clinical Uncertainties
  • 3.3.4 Gene Therapy Safety Concerns
  • 3.3.5 Access and Reimbursement Challenges
• 3.4 Opportunities
  • 3.4.1 Next-Generation Gene Therapies
  • 3.4.2 Gene Editing Technologies
  • 3.4.3 Combination Therapeutic Approaches
  • 3.4.4 Emerging Market Expansion
  • 3.4.5 Precision Medicine Development
• 3.5 Challenges
  • 3.5.1 Long-Term Outcome Validation
  • 3.5.2 Manufacturing Complexity
  • 3.5.3 Rare Disease Clinical Trial Recruitment
  • 3.5.4 Market Access Inequalities

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Pricing Landscape
• 4.3 Reimbursement Environment
• 4.4 Rare Disease Funding Programs
• 4.5 Health Technology Assessment Considerations
• 4.6 Patient Assistance Programs
• 4.7 Commercialization Strategies
• 4.8 Stakeholder Analysis
  • 4.8.1 Patients and Advocacy Groups
  • 4.8.2 Physicians and Treatment Centers
  • 4.8.3 Payers and Insurers
  • 4.8.4 Government Agencies

5. Innovation & Pipeline Landscape

• 5.1 Pipeline Overview
• 5.2 Pipeline by Development Phase
  • 5.2.1 Discovery Stage
  • 5.2.2 Preclinical Stage
  • 5.2.3 Phase I
  • 5.2.4 Phase II
  • 5.2.5 Phase III
• 5.3 Pipeline by Modality
  • 5.3.1 Gene Therapy
  • 5.3.2 Exon-Skipping Therapies
  • 5.3.3 Gene Editing Therapies
  • 5.3.4 Cell-Based Therapies
  • 5.3.5 Small Molecules
  • 5.3.6 RNA-Based Therapeutics
• 5.4 Pipeline by Mechanism of Action
  • 5.4.1 Micro-Dystrophin Replacement
  • 5.4.2 Exon Skipping
  • 5.4.3 Histone Deacetylase Inhibition
  • 5.4.4 Utrophin Modulation
  • 5.4.5 Gene Editing Approaches
  • 5.4.6 Muscle Regeneration Enhancement
• 5.5 Clinical Trial Landscape
  • 5.5.1 Active Clinical Trials
  • 5.5.2 Recruiting Studies
  • 5.5.3 Completed Studies
  • 5.5.4 Regional Clinical Trial Activity

6. Treatment Landscape

• 6.1 Treatment Paradigm Overview
• 6.2 Treatment Guidelines and Standards of Care
• 6.3 Pharmacological Therapies
  • 6.3.1 Corticosteroids
  • 6.3.2 Exon-Skipping Therapies
  • 6.3.3 Gene Therapies
  • 6.3.4 Histone Deacetylase Inhibitors
  • 6.3.5 Supportive Pharmacotherapy
• 6.4 Non-Pharmacological Management
  • 6.4.1 Physical Therapy
  • 6.4.2 Respiratory Support
  • 6.4.3 Cardiac Management
  • 6.4.4 Orthopedic Management
  • 6.4.5 Nutritional Support
• 6.5 Approved Drug Landscape
  • 6.5.1 Deflazacort (Emflaza, Pyquvi, Jaythari)
  • 6.5.2 Eteplirsen (Exondys 51)
  • 6.5.3 Golodirsen (Vyondys 53)
  • 6.5.4 Casimersen (Amondys 45)
  • 6.5.5 Viltolarsen (Viltepso)
  • 6.5.6 Delandistrogene Moxeparvovec (Elevidys)
  • 6.5.7 Vamorolone (Agamree)
  • 6.5.8 Givinostat (Duvyzat)

7. Global Duchenne Muscular Dystrophy Epidemiology Report Size & Forecast

• 7.1 Market Definition and Scope
• 7.2 Historical Market Analysis
• 7.3 Global Market Forecast (2025-2045)
• 7.4 Epidemiology-Based Market Modeling
• 7.5 Forecast by Therapy Type
• 7.6 Forecast by Route of Administration
• 7.7 Forecast by Distribution Channel
• 7.8 Forecast by Geography
• 7.9 Scenario Analysis
  • 7.9.1 Base Case
  • 7.9.2 Optimistic Case
  • 7.9.3 Conservative Case

8. Global Duchenne Muscular Dystrophy Epidemiology Report Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Corticosteroids
  • 8.1.2 Exon-Skipping Therapies
  • 8.1.3 Gene Therapies
  • 8.1.4 Supportive Therapies
• 8.2 By Mutation Type
  • 8.2.1 Exon 45 Amenable
  • 8.2.2 Exon 51 Amenable
  • 8.2.3 Exon 53 Amenable
  • 8.2.4 Other Mutations
• 8.3 By Route of Administration
  • 8.3.1 Oral
  • 8.3.2 Intravenous
  • 8.3.3 Others
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Specialty Clinics
  • 8.4.3 Neuromuscular Centers
  • 8.4.4 Homecare Settings
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.2 Specialty & Retail Pharmacies
  • 8.5.4 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Epidemiology Overview
  • 9.1.2 Market Size and Forecast
  • 9.1.3 Key Growth Drivers
  • 9.1.4 Regional Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Epidemiology Overview
  • 9.2.2 Market Size and Forecast
  • 9.2.3 Key Growth Drivers
  • 9.2.4 Regional Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Epidemiology Overview
  • 9.3.2 Market Size and Forecast
  • 9.3.3 Key Growth Drivers
  • 9.3.4 Regional Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Epidemiology Overview
  • 9.4.2 Market Size and Forecast
  • 9.4.3 Key Growth Drivers
  • 9.4.4 Regional Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Epidemiology Overview
  • 9.5.2 Market Size and Forecast
  • 9.5.3 Key Growth Drivers
  • 9.5.4 Regional Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States - FDA Framework
  • 11.2.1 Orphan Drug Designation
  • 11.2.2 Accelerated Approval Pathways
  • 11.2.3 Gene Therapy Regulations
• 11.3 Europe - EMA Framework
  • 11.3.1 Orphan Medicinal Products
  • 11.3.2 Advanced Therapy Medicinal Products (ATMPs)
• 11.4 Japan - PMDA Framework
  • 11.4.1 Regenerative Medicine Pathways
  • 11.4.2 Conditional Approval Systems
• 11.5 India - CDSCO Framework
  • 11.5.1 Rare Disease Policies
  • 11.5.2 Gene Therapy Regulatory Environment
• 11.6 China - NMPA Framework
  • 11.6.1 Rare Disease Regulations
  • 11.6.2 Innovative Therapy Approval Pathways
• 11.7 Pricing and Reimbursement Policies
• 11.8 Rare Disease Incentive Programs
• 11.9 Future Regulatory Trends

12. Competitive Landscape

• 12.1 Market Structure Analysis
• 12.2 Market Share Assessment
• 12.3 Competitive Benchmarking
• 12.4 Product Positioning Matrix
• 12.5 Pipeline Competitiveness Analysis
• 12.6 Strategic Collaborations and Licensing Agreements
• 12.7 Mergers and Acquisitions
• 12.8 Competitive Intelligence Dashboard

13. Company Profiles

• 13.1 Sarepta Therapeutics
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products
    • 13.1.2.1 Exondys 51 (eteplirsen)
    • 13.1.2.2 Vyondys 53 (golodirsen)
    • 13.1.2.3 Amondys 45 (casimersen)
    • 13.1.2.4 Elevidys (delandistrogene moxeparvovec)
  • 13.1.3 Key Indications
  • 13.1.4 Verified DMD Pipeline Assets
  • 13.1.5 Strategic Outlook
• 13.2 NS Pharma
  • 13.2.1 Company Overview
  • 13.2.2 Approved Product: Viltepso (viltolarsen)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Programs
  • 13.2.5 Strategic Outlook
• 13.3 Catalyst Pharmaceuticals
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products: Agamere (vamorolone)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Programs
  • 13.3.5 Strategic Outlook
• 13.4 Italfarmaco SpA
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product: Duvyzat (givinostat)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Programs
  • 13.4.5 Strategic Outlook
• 13.5 PTC Therapeutics
  • 13.5.1 Company Overview
  • 13.5.2 Approved Product: Translarna (ataluren)*
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Programs
  • 13.5.5 Strategic Outlook
• 13.6 Roche Holding AG
  • 13.6.1 Company Overview
  • 13.6.2 DMD Partnerships and Commercial Rights
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline and Development Programs
  • 13.6.5 Strategic Outlook
• 13.7 Pfizer
  • 13.7.1 Company Overview
  • 13.7.2 Historical DMD Development Programs
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Activities
  • 13.7.5 Strategic Outlook
• 13.8 REGENXBIO
  • 13.8.1 Company Overview
  • 13.8.2 DMD Gene Therapy Programs
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Status
  • 13.8.5 Strategic Outlook
• 13.9 Solid Biosciences
  • 13.9.1 Company Overview
  • 13.9.2 DMD Development Programs
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Status
  • 13.9.5 Strategic Outlook
• 13.10 Dyne Therapeutics
  • 13.10.1 Company Overview
  • 13.10.2 DMD Development Programs
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Status
  • 13.10.5 Strategic Outlook

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Therapeutic Innovations
• 14.3 Gene Editing Outlook
• 14.4 Precision Medicine Evolution
• 14.5 Market Forecast Scenarios Through 2045
• 14.6 Key Strategic Recommendations
• 14.7 Analyst Conclusions

15. Methodology

• 15.1 Research Methodology Overview
• 15.2 Secondary Research Sources
• 15.3 Primary Research Framework
• 15.4 Epidemiology Modeling Methodology
• 15.5 Forecasting Assumptions
• 15.6 Data Validation Process
• 15.7 Quality Control Framework
• 15.8 Disclaimer and Limitations